Related Experiment Videos
[Tigecycline: a new antibiotic in ongoing clinical development]
1Service des maladies infectieuses et tropicales, CHU de Grenoble, BP217, 38043 Grenoble cedex 09, France. jpstahl@chu-grenoble.fr
Medecine Et Maladies Infectieuses
|March 23, 2005
Summary
Tigecycline shows broad-spectrum activity against resistant bacteria, including Gram-positive and Gram-negative pathogens. Phase II trials indicate good tolerance and efficacy for skin and intra-abdominal infections, offering a new option against antimicrobial resistance.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Antimicrobial resistance poses a significant public health threat.
- Development of new broad-spectrum antibiotics is limited.
- Tigecycline represents a novel glycylcycline antibiotic class.
Purpose of the Study:
- To evaluate the in vitro activity of tigecycline.
- To assess the safety and efficacy of tigecycline in clinical trials.
- To determine tigecycline's potential role in treating infections caused by resistant pathogens.
Main Methods:
- In vitro susceptibility testing against various bacterial pathogens.
- Phase II clinical trials evaluating intravenous tigecycline administration.
- Assessment of treatment outcomes for complicated skin and intra-abdominal infections.
Main Results:
- Tigecycline demonstrated broad in vitro activity against Gram-positive (e.g., Staphylococcus aureus) and Gram-negative (e.g., Haemophilus influenzae) pathogens, including resistant strains.
- The drug showed efficacy against some anaerobic bacteria.
- Phase II trials reported good tolerance and effectiveness in treating complicated skin and intra-abdominal infections.
Conclusions:
- Tigecycline exhibits promising broad-spectrum antimicrobial activity.
- Clinical trial data suggest favorable safety and efficacy profiles.
- Tigecycline could become a valuable addition to the antibacterial armamentarium, especially for severe or hospital-acquired infections caused by resistant organisms.